Biomarkers in the Retina for Prognosticating Mental Health Treatments
Key facts
- Who runs it
- VA Puget Sound Health Care System
- Where
- Seattle, United StatesSee the site
- Trial code
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 12 Feb 2024
- Expected to end
- 1 Sept 2030
- Type of study
- Interventional
- Treatments tested
- RETeval
- Record updated
- 12 April 2024
Who can take part
- Age
- 21 years to 75 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Veteran of the U.S. Armed Forces
- Current diagnosis of PTSD
Who cannot take part
- Previous ERG deficits
- Allergy or previous adverse reaction to sertraline or SSRI
- Any use in the time period of at least 6 half-lives prior to baseline of sertraline or other drugs acting on serotonin and/or unwillingness to avoid these medications for the duration of the study
- Known diagnosis of a primary psychotic or major neurocognitive disorder
- History of acute angle closure glaucoma
- Known inherited retinal disease
- Known photosensitive epilepsy
- Allergy to Sensor Strip gel
- Hepatic failure
- Significant bilateral visual loss
- Known current pregnancy or lactation
- Damage to orbit structure or open lesion in soft tissue surrounding the eye
The main criteria, as questions
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 21 and 75 years old?
Where in United States
- VA Puget Sound Health Care SystemSeattle, United StatesContact: Rebecca C Hendrickson, MD, PhDTaking people
About the trial
What the trial wants to find out
Title: ERG as a potential biomarker of SSRI-responsive PTSD: A pilot study
Read full original descriptionShow less
Posttraumatic stress disorder (PTSD) affects many individuals who experience a traumatic event. Previous studies suggest that there is a connection between the brain and the retina, and that the electroretinogram (ERG) may be a valuable biomarker to tell us more about signals in the brain that are related to mental health disorders like PTSD. The goal of this observational study is to examine the ERG waveform in veterans with PTSD before and after a single dose of the selective serotonin reuptake inhibitor (SSRI), sertraline. Sertraline is one of two FDA-approved medications for the treatment of PTSD. The main questions this pilot study aims to answer are:
1. How does sertraline, an SSRI, influence the ERG waveform in veterans with PTSD? 2. Is there a significant correlation between baseline ERG signals and the change in ERG following SSRI treatment?
Participants will be asked to:
* Undergo ERG recordings before and after a single dose of sertraline. * Provide relevant clinical information related to PTSD symptoms and treatment history.
Following the initial study visits, participants will enter an optional open label phase of the study in which qualifying participants who initiate antidepressant treatment through routine clinical care will be invited back for a follow-up ERG recording.
The group in the trial
- ERG, all participantsTreatment being tested
All participants undergo ERG recording before and after a single dose of sertraline 50 mg.
Treatment: RETeval
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Electroretinogram (ERG) as a Potential Biomarker of Serotonin Selective Reuptake Inhibitor (SSRI)-Responsive Posttraumatic Stress Disorder (PTSD): A Pilot Study
- Criteria questions
- Built from NCT06363968, who can take part
- Record updated
- 12 April 2024